Breaking News: Capvaxive Approved!

Merck & Co, known as MSD in many parts of the world, has just received a major thumbs-up from the Medicines and Healthcare products Regulatory Agency (MHRA) for its groundbreaking pneumococcal vaccine, Capvaxive.

Why This Vaccine is a Game-Changer

Capvaxive is specifically formulated for adults ages 18 and up, aiming to combat serious diseases caused by the notorious Streptococcus pneumoniae bacteria. This includes pneumonia and meningitis, which the World Health Organization (WHO) has flagged as a significant public health threat.

What Makes Capvaxive Stand Out?

This innovative vaccine is a 21-valent formulation, meaning it targets 21 different strains of pneumococcal bacteria—especially the ones that most commonly lead to severe invasive diseases in adults.

Fast-Tracked Approval: How Did It Happen?

The MHRA’s approval was expedited via the International Recognition Procedure, leveraging previous endorsements from world regulatory partners. Notably, the European Commission green-lighted Capvaxive back in March, paving the way for the MHRA’s decision.

Impressive Trial Results!

Clinical trials have shown that Capvaxive packs a punch—producing immune responses in adults aged 50 and older that are comparable to Pfizer’s 20-valent vaccine, PCV20. Even more striking, it generated superior immune responses against ten of its unique serotypes!

Safety Comes First!

The MHRA assures the public that the safety and effectiveness of Capvaxive will remain under close scrutiny even post-approval. Emma Cerrone, director of the vaccines business unit for MSD UK, expressed excitement about the approval, emphasizing the vaccine’s potential in preventing serious pneumonia and reducing hospitalizations.

Global Reach of Capvaxive

Not only is Capvaxive approved in the UK and Europe, but it has also gained approval in the US, Canada, and Australia—making it a vital tool in global health.

A Brighter Future Awaits!

With Capvaxive's approval, adults around the world now have a powerful ally in the fight against pneumococcal diseases. Stay informed and protect your health!